Skip to main content
. 2020 May 29;52:110–115. doi: 10.1016/j.breast.2020.05.006

Table 2.

Primary systemic therapy versus upfront surgery in specific conditions: T1cN0 triple negative and pT1c-ER negative HER2 positive breast cancer.

Breast cancer subtype Primary treatment Before COVID-19 During COVID-19 P value
T1cN0 triple negative Chemotherapy 227 (60.2%) 186 (49.3%) 0.002
Surgery 150 (39.8%) 191 (50.7%)
ER negative HER2 positive pT1c Chemotherapy in combination with anti HER2 therapy 250 (66.3%) 218 (57.8%) 0.016
Surgery 126 (33.7%) 159 (42.2%)